Latest News Breakthrough at 2026 AACR! Senhwa Biosciences’ CX-5461 Enters the Field of Photodynamic Therapy, Opening a New Indication Strategy Mar 17 2026 Latest News Senhwa Biosciences Signs Major Strategic MOU with Y Combinator-Backed AI Biotech Company CellType to Accelerate the Evolution of CX-4945 into Version 2.0 and Reshape the Global Immunotherapy Landscape Mar 03 2026 Latest News Senhwa Biosciences Aims at Multi-Billion Dollar Global Market with CX-5461 Combined with ADC “Blockbuster” Therapy Dec 29 2025 Media Coverage Taiwan's Senhwa Biosciences inks immunotherapy deal with US biotech firm CellType Mar 04 2026 Media Coverage Senhwa Biosciences Partners with BeOne for Advanced Cancer Treatment Dec 11 2025 Media Coverage Google's AI model identified Silmitasertib (CX-4945) as a potential key to boosting tumor antigen presentation by turning cold tumors to hot ones, a new potential cancer therapy pathway. Oct 16 2025 Publications Targeting ribosomes reprograms the tumour microenvironment and augments cancer immunotherapy Jul 11 2025 Publications Targeting WDR5/ATAD2 signaling by the CK2/IKAROS axis demonstrates therapeutic efficacy in T-ALL Mar 27 2025 Publications Fibroblast growth receptor 1 is regulated by G-quadruplex in metastatic breast cancer Aug 09 2024